-
Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in U.S. military veterans by medication type.
Hayes CJ, Raciborski RA, Nowak M, Acharya M, Nunes EV, Winhusen TJ. Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in U.S. military veterans by medication type. Addiction 2025;120(1):138-151.
-
Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial.
Winhusen TJ, Kropp F, Smid MC, Young JL, Davies TH, Lewis D, Rosa C, Dilawar M, Krans EE, Hodgkins C, Cochran G, Lofwall MR. Personally-tailored opioid-overdose and medication for opioid use disorder (MOUD) education (TOME) significantly increases MOUD and overdose knowledge in peripartum individuals: Results from a randomized controlled pilot trial. Drug and Alcohol Dependence 2025;275:112795.
-
Research agenda evaluating measurement-based care for opioid use disorder among patients with co-occurring depressive disorders [opinion].
Ghitza UE. Research agenda evaluating measurement-based care for opioid use disorder among patients with co-occurring depressive disorders [opinion]. Frontiers in Psychiatry 2025;16:1624642.
-
Craving, impulsivity, and subsequent methamphetamine use with naltrexone-bupropion versus placebo: Findings from a randomized clinical trial.
Jha MK, Ghitza UE, Carmody T, Kuruvila N, Shoptaw S, Minhajuddin A, Wakhlu S, Schmitz JM, Coffin PO, Bart G, Nunes EV, Kenny P, Trivedi MH. Craving, impulsivity, and subsequent methamphetamine use with naltrexone-bupropion versus placebo: Findings from a randomized clinical trial. Journal of Addiction Medicine 2025 (in press).
-
Using structural equation modeling to examine barriers and facilitators of HIV pre-exposure prophylaxis willingness and length of use in men who have sex with men who use substances in eight southern US cities.
Ertl M, Woodhouse C, Meche D, Forrest DW, Fegley JP, Paschen-Wolff M, Laschober TC, Hatch MA, Nelson CM, Wright L, Tross S. Using structural equation modeling to examine barriers and facilitators of HIV pre-exposure prophylaxis willingness and length of use in men who have sex with men who use substances in eight southern US cities. AIDS Patient Care and STDs 2025;39(6):245-256.
-
Conducting an implementation intervention study with American Indian and Alaska Native communities: Methodological considerations.
Paschen-Wolff MM, Campbell ANC, Vasquez A, Kessler J, Jansen K, Arnatt CP, Rosa C, Hebden HM, Radin S, Stately A, Shaw J, Kennedy F, Matthews AG, Venner KL. Conducting an implementation intervention study with American Indian and Alaska Native communities: Methodological considerations. Contemporary Clinical Trials 2025;107992.
-
Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design.
Trivedi MH, Kalmin MM, Carmody T, Chongsi EM, Ghitza UE, Jha MK, Mayes TL, Casey-Willingham A, Sethuram S, Marino EN, Monastirsky M, Shoptaw SJ. Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design. Contemporary Clinical Trials 2025;154:107954.
-
Early change in depressive symptom severity with naltrexone-bupropion combination and its association with reduction in methamphetamine use in ADAPT-2 trial.
Jha MK, Ghitza UE, Shoptaw S, Minhajuddin A, Kuruvila S, Wakhlu S, Nunes EV, Schmitz J, Coffin PO, Bart G, Carmody T, Trivedi MH. Early change in depressive symptom severity with naltrexone-bupropion combination and its association with reduction in methamphetamine use in ADAPT-2 trial. Journal of Clinical Psychiatry 2025;86(3):25m15825.
-
“I don’t tell anyone I have them”: Experiences with opioid stigma from the perspective of survivors living with chronic cancer-related pain and clinicians that care for them.
Bell SG, Hamm M, Wasilewski J, Wasiko R, Olejniczak D, Subramaniam GA, Liebschutz J, Bulls HW. "I don't tell anyone I have them": Experiences with opioid stigma from the perspective of survivors living with chronic cancer-related pain and clinicians that care for them. Journal of Pain 2025;32:105411.
-
Identifying alcohol use disorder and problem use in adult primary care patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool with the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C).
Adam A, Laska E, Schwartz RP, Wu L, Subramaniam GA, Appleton N, McNeely J. Identifying alcohol use disorder and problem use in adult primary care patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool with the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C). Substance Use & Addiction Journal 2025;46(3):686-694.